【レポートの概要（一部）】
1. Executive Summary
1.1 Biosimilars: World Market Review 2014
1.2 Report Contents
1.2.1 Benefits of this Report
1.3 Report Methods
1.3.1 Financial Information in this Report
1.3.2 Who is this Report for?
1.4 An Introduction to Biosimilars and Biosimilar Drug Development
1.4.1 A Brief History of Biological Drug Development
1.4.2 The Advent of Biosimilars
1.4.2.1 What Is a Biosimilar?
1.4.3 What Is Driving Demand for Biosimilar Development?
1.4.4 What Has Slowed Biosimilar Drug Development?
1.4.5 Important Sectors of the Biosimilar Market
2. The World Biosimilars Market: Outlook and Forecast 2014-2024
2.1 The World Biosimilars Market 2013
2.1.1 Biosimilars as a Share of the Biologics Market, 2013
2.1.2 Eleven Drugs Account for More than 50% of Biological Drug Revenues
2.1.3 Leading Biologics Sectors Represent Leading Targets for Biosimilars
2.2 Outlook for the World Biosimilars Market 2014-2024
2.2.1 Revenue Growth in the Biologics Market 2014-2024
2.2.2 Biosimilars Market Forecast 2014-2024
2.2.3 Changing Market Shares for Leading Segments 2014-2024
2.2.4 What Will Drive Growth in the Biosimilars Market to 2024?
2.2.5 Biosimilars Market Restraints, 2014-2024
3. Biosimilars in Leading Developed Markets 2014-2024
3.1 Which Were the Leading National Submarkets for Biosimilar Sales in 2013?
3.1.1 Growth in Leading Developed Markets to 2024
3.2 The Outlook for Biosimilars in the US 2014-2024
3.2.1 When Will Finalised FDA Development Guidelines be Released?
3.2.1.1 A Fourth Draft Guideline Released in 2013
3.2.2 US States Introduce their Own Biosimilar Rules
3.2.3 US Biosimilars Submarket Forecast, 2014-2024
3.2.3.1 What Rates of Uptake Can We Expect for Biosimilars in the US?
3.3 Biosimilars in the EU: Outlook 2014-2024
3.3.1 The EU Led the World in Biosimilar Regulation
3.3.2 The EMA Updates its Overarching Guidelines 2012-2014
3.3.3 Biosimilar Uptake in the EU 2008-2013
3.3.4 The EU Biosimilars Submarket Forecast 2014-2024
3.3.4.1 Biosimilar MAbs in the EU from 2014
3.3.5 Biosimilars in Germany: High Uptake for Current Biosimilars
3.3.5.1 German Biosimilars Submarket: Revenue Forecast 2014-2024
3.3.6 The French Biosimilars Submarket 2014-2024
3.3.6.1 New Rules Introduce the Possibility of Biosimilar Substitution
3.3.6.2 French Biosimilars Submarket Forecast 2014-2024
3.3.7 Biosimilars in the UK: High Uptake for Filgrastim
3.3.7.1 UK Biosimilars Submarket Forecast 2014-2024
3.3.8 The Italian Biosimilars Submarket Forecast 2014-2024
3.3.9 Outlook for Biosimilars in Spain: Submarket Forecast 2014-2024
3.4 The Japanese Biosimilars Submarket 2014-2024
3.4.1 Biosimilar Regulation in Japan 2014
3.4.1.1 Differences Exist Between EU and Japanese Guidelines
3.4.2 Collaboration Agreements Drive Biosimilar Development in Japan
3.4.3 Biosimilar MAbs Could be Launched in 2014
3.4.4 Japanese Biosimilars Submarket Forecast 2014-2024
4. Outlook for Biosimilars in Emerging Markets 2014-2024
4.1 China and India Lead in Biosimilar Range and Revenues 2014
4.1.1 Biosimilar Growth in Emerging National Markets 2014-2024
4.2 Outlook for the Chinese Biosimilars Submarket 2014-2024
4.2.1 Biosimilar Development Guidelines Set for Release
4.2.2 Biosimilars Account for Less than Half of Biotech Revenues in China
4.2.3 Chinese Biosimilars Submarket Forecast 2014-2024
4.3 Biosimilars in India: Regulatory and Commercial Outlook 2014-2024
4.3.1 CDSCO Guidelines Released in 2012: How will they Affect Developers?
4.3.2 Biosimilar Uptake in India 2014
4.3.3 Strong Growth Forecast for the Indian Biosimilars Submarket 2014-2024
4.4 The Brazilian Biosimilars Submarket 2014-2024
4.4.1 Biosimilar Regulations Are Similar to those in the EU
4.4.2 Promoting Domestic Biosimilar and Biologic Development
4.4.3 Brazilian Biosimilar Submarket Forecast 2014-2024
4.5 What Potential is there for Biosimilars in Russia to 2024?
4.5.1 No Specific Guidelines for Biosimilar Development
4.5.2 Russian Biosimilars Submarket Forecast 2014-2024
4.6 South Korea: A Leading Country for Biosimilar Development
4.6.1 Established Biologic and Biosimilar Guidelines
4.6.2 Local Players Are Keen on Biosimilar MAb Development
4.6.3 South Korean Biosimilars Submarket Forecast 2014-2024
5. Biosimilar Monoclonal Antibodies and Fusion Proteins: Submarket Forecast and Pipeline 2014-2024
5.1 Monoclonal Antibodies (MAbs): The Largest Biologics Market Sector in 2013
5.1.1 High Demand in Cancer and Autoimmune Disease
5.2 The MAbs Submarket Forecast 2014-2024
5.2.1 Rising Disease Incidence to Stimulate Sales Growth
5.2.2 MAbs: Product and Portfolio Lifecycle Management
5.3 Biosimilar MAbs Outlook 2014-2024
5.3.1 There Are Challenges in Antibody Development and Manufacturing
5.3.2 Partnering to Launch Biosimilar MAbs
5.3.3 Biosimilars MAbs Submarket Forecast 2014-2024
5.3.4 Multiple Product Launches Will Drive Submarket Growth
5.3.5 Biosimilar MAbs and FPs: Submarket Restraints 2014-2024
5.3.6 Leading Targets for Biosimilar Development 2014-2024
5.4 Biosimilar Rituximab 2014-2024
5.4.1 Three Biosimilars Available in 2014
5.4.1.1 Reditux (Dr. Reddy’s Laboratories)
5.4.1.2 Mabtas: A Second Indian Biosimilar
5.4.1.3 Kikuzubam: Removed from the Market, 2014
5.4.2 Biosimilar Rituximab: Revenue Forecast 2014-2024
5.4.3 Biosimilar Rituximab Pipeline 2014
5.4.3.1 A Reduced Late-Stage Pipeline 2012-2014
5.4.3.2 GP2013 (Sandoz): The Most Advanced Developed-Market Candidate
5.4.3.3 BI 695500 (Boehringer Ingelheim)
5.4.3.4 MabionCD20 (Mabion)
5.4.3.5 BCD020 (Biocad)
5.4.3.6 CT-P10 (Celltrion): Development Delayed
5.4.3.7 PF-05280586 (Pfizer)
5.5 Biosimilar Infliximab 2014-2024
5.5.1 Hospira and Celltrion: Biosimilars for Developed Markets
5.5.1.1 Egis Pharmaceuticals Launches Flammegis in Eastern Europe
5.5.2 Biosimilar Infliximab: Revenue Forecast 2014-2024
5.5.3 Biosimilar Infliximab Pipeline 2014
5.5.3.1 BOW-015 (Epirus Biopharmaceuticals)
5.5.3.2 R-TPR-015 (Reliance Life Sciences)
5.5.3.3 Nichi-Iko: A Second Biosimilar for Japan
5.6 Biosimilar Trastuzumab 2014-2024
5.6.1 Biocon/Mylan: Biosimilar Approval in India
5.6.1.1 Roche Sues Biocon and Mylan over Hertraz Launch
5.6.2 Herzuma: Approved in South Korea 2014
5.6.3 Biosimilar Trastuzumab: Revenue Forecast 2014-2024
5.6.4 Biosimilar Trastuzumab Pipeline: Four Clinical-Stage Candidates in 2014
5.6.4.1 Amgen and Actavis Advance to Phase III
5.6.4.2 PF-05280014 (Pfizer): Phase III Launched 2014
5.6.4.3 BCD-022 (Biocad): A Third Phase III Biosimilar
5.7 Biosimilar Adalimumab 2014-2024
5.7.1 Humira is the World’s Leading Antibody Therapy
5.7.2 AbbVie Seeks to Protect its Lead Asset
5.7.3 Biosimilar Adalimumab: Revenue Forecast
5.7.4 First Biosimilar to Launch in India
5.7.4.1 Amgen Advances to Phase III
5.7.4.2 GP2017 (Sandoz)
5.7.4.3 Phase I Biosimilar Adalimumab Candidates
5.8 Biosimilar Etanercept 2014-2024
5.8.1 Enbrel Is the Leading Fusion Protein
5.8.2 Extended Patent Protection in the US
5.8.3 Biosimilars Are Available in Emerging National Markets
5.8.4 Biosimilar Etanercept: Revenue Forecast 2014-2024
5.8.5 Biosimilar Etanercept Pipeline 2014
5.8.5.1 GP2015 (Sandoz)
5.8.5.2 CHS-0214 (Coherus BioSciences)
5.8.5.3 Hanwha Chemical: Submitted in South Korea
5.8.5.4 TuNEX (Mycenax Biotech)
5.9 Other Leading Antibody Targets 2014-2024
5.9.1 Avastin Loses Patent Protection in 2018
6. Biosimilar Insulin Submarket Outlook 2014-2024
6.1 Insulin: The Second-Largest Biological Drug Sector 2014
6.1.1 Insulin Submarket Forecast 2014-2024
6.1.2 Diabetes Prevalence Is Rising Worldwide
6.2 Biosimilar Insulin Submarket 2014-2024
6.2.1 There Are No Biosimilars in Developed Markets in 2014
6.2.2 Biosimilar Insulin Submarket Forecast 2014-2024
6.2.3 Launch of Biosimilar Insulin Analogues to Stimulate Growth from 2014-2024
6.2.4 Biosimilar Insulin Submarket Restraints 2014-2024
6.3 Biosimilar Human Insulin Submarket 2014-2024
6.3.1 A Submarket Restricted to Emerging Markets?
6.3.2 Biosimilar Human Insulin in China
6.3.2.1 Biosimilar Insulin Uptake in China 2014
6.3.3 Biosimilar Human Insulin in India
6.3.3.1 What Share Do Biosimilars Hold of the Indian Insulin Submarket?
6.3.3.2 Indian Developers Target the US and EU?
6.3.4 Biosimilar Human Insulin in Other Emerging Markets
6.3.5 Biosimilar Human Insulin Submarket Forecast 2014-2024
6.4 Biosimilar Insulin Analogues 2014-2024
6.4.1 Insulin Analogues Account for Three Quarters of Global Insulin Revenues
6.4.2 Insulin Glargine Is the Main Biosimilar Target
6.4.3 Biosimilar Insulin Analogue Revenue Forecast 2014-2024
6.4.4 Insulin Market Leaders Are Developing Ultra-Acting Insulin Analogues
6.5 Biosimilar Insulin Glargine 2014-2024
6.5.1 Two Biosimilars Are Available in India
6.5.1.1 Mylan Partners with Biocon for Insulin Analogues
6.5.2 Biosimilar Insulin Glargine: Revenue Forecast 2014-2024
6.5.3 Ultra-Long Acting Insulin Analogues in Development
6.5.4 Biosimilar Insulin Glargine Pipeline 2014
6.5.4.1 Eli Lilly and Boehringer Ingelheim Submit Approval Applications in the EU and US
6.5.4.2 Merck & Co. Partners with Samsung Bioepis
6.6 Biosimilar Insulin Lispro 2014-2024
6.6.1 One Biosimilar Available in 2014
6.6.2 Biosimilar Insulin Lispro Revenue Forecast 2014-2024
6.6.3 Ultra-Rapid Acting Insulin: New Options from 2014
6.6.4 Biosimilar Insulin Lispro Pipeline 2014
6.6.4.1 Insulin Lispro Biosimilars in India
7. Biosimilar Erythropoietins: Future Directions 2014-2024
7.1 Three Products Lead the EPO Therapy Submarket in 2014
7.1.1 Aranesp and Procrit: Falling Revenue 2011-2013
7.1.2 Safety Concerns for Erythropoietin-Stimulating Agents
7.2 EPO Submarket Forecast 2014-2024
7.2.1 The Challenge from Oral Therapies Is Coming
7.2.2 Prevalence of Chronic Kidney Disease Will Rise 2014-2024
7.3 The Biosimilar EPO Submarket 2014-2024
7.3.1 Biosimilar Epoetin in the EU 2006-2013
7.3.1.1 Pipeline Epoetin Alpha for the EU Submarket 2014
7.3.1.2 Trends in Uptake for Biosimilar Epoetins in the EU
7.3.2 Companies Preparing for US Launch in 2015
7.3.2.1 The US Is an Appealing Submarket for Developers
7.3.3 Biosimilar Epoetin: Japanese Submarket Overview 2010-2013
7.3.4 Biosimilar Epoetins in Emerging Markets: Multiple Players in a Fragmented Market
7.3.5 Second-Generation EPO Biosimilars
7.3.5.1 Biosimilar Darbepoetin Alpha Pipeline 2014
7.3.6 Biosimilar EPO Submarket Forecast 2014-2024
8. Biosimilar G-CSF: Outlook and Forecast 2014-2024
8.1 Amgen Leads the G-CSF Submarket in 2014
8.1.1 G-CSF Submarket Outlook and Forecast 2014-2024
8.1.2 Teva Launches Long-Acting Pegfilgrastim
8.1.2.1 Other Long-Acting Therapies in Development
8.2 The Biosimilar G-CSF Submarket 2014
8.2.1 One of the First Biosimilars in the EU and US
8.2.1.1 Zarzio Is the Most Prescribed Filgrastim Therapy in Europe
8.2.1.2 Tevagrastim: The First EU Biosimilar
8.2.1.3 Nivestim (Hospira)
8.2.2 Multiple Launches in Japan 2013-2014
8.2.3 Biosimilar Pegfilgrastim and Filgrastim in Emerging Markets
8.2.3.1 A Competitive Biosimilar Submarket in Russia
8.3 Biosimilar G-CSF Submarket 2014-2024
8.3.1 Biosimilar G-CSF Submarket Forecast 2014-2024
8.3.2 Biosimilar G-CSF Submarket: US Launches to Drive Growth 2014-2024
8.3.3 Trends in Biosimilar Uptake in the EU 2008-2013
8.3.4 Biosimilars Targeting the US Submarket
8.4 Biosimilar Pegfilgrastim: Pipeline 2014
8.4.1 Sandoz Leads the Way for Developed Markets
8.4.2 Hospira Gains Funding for Parallel Filgrastim and Pegfilgrastim Development
9. Biosimilar Interferons Submarket 2014-2024
9.1 Steady Growth in the Interferon Alpha and Beta Submarkets 2011-2013
9.1.1 Many Challengers Exist in the Multiple Sclerosis Market
9.1.2 All-Oral Regimens Will Challenge Interferon Alpha Therapy
9.1.2.1 Oral Therapies Will be High Cost
9.2 Interferon Submarket Forecast: Falling Revenue to 2024
9.3 Biosimilar Interferon Submarket 2013
9.3.1 There Are No Biosimilars Approved in Developed Markets
9.3.2 Biosimilar Interferon Submarket Forecast 2014-2024
9.4 Biosimilar Interferon Alpha 2014-2024
9.4.1 Biosimilar Interferon Alpha Is a Common Target in BRIC Nations
9.4.2 Biosimilar Peginterferon Alpha Pipeline 2014
9.4.3 Hepatitis Is a Growing Problem in Emerging Markets
9.4.4 Biosimilar Interferon Alpha Submarket Forecast 2014-2024
9.5 Biosimilar Interferon Beta 2014-2024
9.5.1 Biosimilars Are Well-Established in Emerging Markets
9.5.1.1 Biosimilar Interferon Beta Pipeline 2014
9.5.2 Will EMA Guidance Drive Development in the EU?
9.5.3 Long-Acting Interferon Beta to Launch in 2014
9.5.4 Biosimilar Interferon Beta Submarket Forecast 2014-2024
10. Recombinant Hormones: Biosimilar Submarket Outlook 2014-2024
10.1 Biosimilar Growth Hormones Submarket 2014-2024
10.1.1 Novo Nordisk and Pfizer Dominate the Growth Hormones Submarket
10.1.2 Product Lifecycle Management Will Maintain Revenues for Submarket Leaders 2014-2024
10.1.3 Biosimilar Growth Hormone Submarket 2013
10.1.3.1 Omnitrope: The World’s Bestselling Biosimilar
10.1.4 Many Biosimilars Are Available Worldwide
10.1.4.1 Biosimilar Growth Hormones in Japan and China
10.1.5 Biosimilar Uptake Varies by Region
10.1.6 Biosimilar Growth Hormone Submarket Forecast 2014-2024
10.2 Biosimilar Fertility Hormones Submarket 2014-2024
10.2.1 Two Products Lead the Fertility Hormone Submarket 2014
10.2.2 Long-Acting Follicle-Stimulating Hormone (FSH)
10.2.3 Fertility Hormone Submarket Forecast 2014-2024
10.2.4 Biosimilar Fertility Hormones 2014-2024
10.2.4.1 Two Biosimilars Approved in the EU 2013-2014
10.2.4.2 Biosimilars Beyond FSH 2014
10.2.5 Biosimilar Fertility Hormone Submarket Forecast 2014-2024
10.2.6 Rising Infertility to Drive Demand to 2024
11. Biosimilars and Follow-On Biologics: Industry Trends 2014-2024
11.1 Biosimilars Market: Strengths 2014
11.1.1 Biosimilars Are Available and Well-Established in Many National Markets
11.1.2 Leading Classes of Biological Drug Face Biosimilar Competition
11.1.3 Biosimilars Offer Cost Savings
11.1.4 Outsourcing Offers the Chance for Further Cost Savings
11.2 Biosimilars Market: Weaknesses 2014
11.2.1 Uptake for Most Biosimilars Remains Low in 2014
11.2.2 Biosimilars Are High Cost to Develop and Manufacture
11.2.3 Development Timelines for Biosimilars Are Long
11.2.4 Few Companies Dominate the Late-Stage Pipeline
11.2.5 Awareness of Biosimilars Remains Low
11.3 Biosimilars Market: Opportunities 2014-2024
11.3.1 The Pipeline for New Biosimilars Is Long
11.3.2 Blockbuster Biologics Face Patent Expiry
11.3.3 Rising Disease Chronic Disease Prevalence
11.3.4 Licensing Agreements for Biosimilars
11.3.5 The Opportunity for Biosimilar Substitution?
11.4 Biosimilars Market: Threats 2014-2024
11.4.1 The Threat of Biobetters and Next-Generation Biologics
11.4.2 Product Lifecycle Management to Extend Branded Revenues
11.4.3 Many Companies Are Chasing the Same Targets
11.4.4 Long Market and Data Exclusivity Periods Will Slow Biosimilar Development
11.4.5 Biosimilars Require Marketing
11.5 Porter’s Five Forces Analysis for the Biosimilars Market 2014-2024
11.5.1 Rivalry Among Competitors
11.5.2 Threat of New Entrants
11.5.3 Bargaining Power of Suppliers
11.5.4 Bargaining Power of Buyers
11.5.5 Threat of Substitutes
12. Research Interviews
12.1 Dr Don Stewart, CEO, PlantForm
12.1.1 Benefits in Plant-Based Systems
12.1.1.1 PlantForm Uses Tobacco Plants
12.1.2 Technological Challenges in Plant-Based Systems
12.1.3 Developing Biosimilars for North America and Europe
12.1.4 Differentiating Biosimilar Antibodies
12.1.5 The Threat of Biobetters
12.1.6 PlantForm’s Biosimilar Development
12.1.7 Biosimilar Development for Emerging Markets
12.2 Biosidus
12.2.1 Current Biosimilars Business and Product Portfolio
12.2.2 Regional Competition Facing Biosidus
12.2.3 Future Strategies for Growth and Company Threats
13. Conclusions of the Research and Analysis
13.1 The Biosimilars Market Will Grow Strongly to 2024
13.2 Biosimilar MAb Development Will Lead the Market
13.3 Rising Costs Will Drive Demand for Biosimilars
13.4 Challenges Remain in Developing and Successfully Launching Biosimilars
【レポート販売概要】
■ タイトル：世界におけるバイオシミラー及び後続生物製剤市場（2014-2024）■ 英文：Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024
■ 発行日：2014年5月
■ 調査会社：visiongain
■ 商品コード：Visiongain-4052662
■ 調査対象地域：グローバル
- 茶（緑茶、紅茶）市場（～2019）：世界市場The expansion of the global tea industry is forecast to reach 5.8% p.a. in the coming years. Between 2008 and 2014 the market increased with an average annual growth of 10.0%. Currently, green tea (unfermented) accounts for 43.2% of the global demand while the remaining market share is divided between black tea (fermented or partly fermented) (29.8%) and tea concentrates, extracts and essences (27 …
- チルドビーム装置の世界市場：アクティブチルドビーム、パッシブチルドビーム、マルチサービスチルドビームChilled beam systems comprise air conditioning and ventilation systems that are capable of providing energy-efficient thermal comfortto occupants in several building applications such as commercial offices, hotels, healthcare facilities, educational institutions, and others.It also helps users increase theirreturn on investment (ROI) and reduces the costs significantly by saving energy up to 40% o …
- 急性高度難聴(Acute Sensorineural Hearing Loss)の治療薬パイプライン動向（2015年上半期版）Acute Sensorineural Hearing Loss - Pipeline Review, H1 2015 Summary Global Markets Direct’s, ‘Acute Sensorineural Hearing Loss - Pipeline Review, H1 2015’, provides an overview of the Acute Sensorineural Hearing Loss’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Acute Sensorineural Hearing Loss, complete with comparative analysis at vario …
- Alexander Energy Ltd.：石油・ガスの開発・生産動向及びコスト分析- Q3, 2013Alexander Energy Ltd. Oil & Gas Exploration and Production Operations and Cost Analysis - Q3, 2013 Summary Alexander Energy Ltd. Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential source …
- ポリアルキレングリコールの世界市場2018-2022About Polyalkylene Glycol Polyalkylene glycol is formed by the reaction of an alcohol with one or more alkylene oxides such as propylene oxide and ethylene oxide.· Polyalkylene glycol is divided into two different product types: Polypropylene glycol and polyethylene glycol. It is used in various applications such as PU foams, lubricants, personal care, pharmaceuticals, and others in regions such a …
- 農業用着色剤の世界市場予測（～2022年）：染料、顔料The agricultural colorants market is estimated at USD 1.63 Billion in 2017, and is projected to reach USD 2.03 Billion by 2022. The primary factors influencing the agricultural colorants market are increased usage of advanced agricultural techniques, increase in awareness among farmers, multifunctionality of the agricultural colorants market, and rise in demand from the end-use industries, due to …
- 世界の酪農食品（乳製品）市場のニュース及びイベント動向（2014年7月）Synopsis The report provides a review of the latest news and key events in the global dairy food market during July 2014. Summary Using this report, marketers will effectively gain an insight into the latest happenings in the global dairy food market throughout the month. The monthly report provides the reader with the top-line data necessary to quickly keep abreast of latest events in the global …
- 世界の電磁弁市場2015The Global Solenoid Valves Industry Report 2015 is a professional and in-depth study on the current state of the Solenoid Valves industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Solenoid Valves market analysis is provided for the international markets including development trends, competitive lands …
- 自動車用電気油圧式パワーステアリングシステムの世界市場展望2017-20276According to Stratistics MRC, the Global Automotive Electro-hydraulic Power Steering System Market is growing at a CAGR of 12.8% during the forecast period. Some of the key factors influencing the market growth include rising penetration of 48V electrical architecture in modern vehicles and development of steer-by-wire systems. However, high cost associated with power steering system is restrainin …
- Santos Ltd.：石油・ガスの開発・生産動向及びコスト分析– Q1, 2013Santos Ltd. Oil & Gas Exploration and Production Operations and Cost Analysis – Q1, 2013 Summary Santos Ltd. Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential source for key operational …
- 尿道カテーテルの世界市場：間欠カテーテル、フォーリーカテーテル、男性用外付けカテーテルAbout Urinary Catheters Urinary catheters are devices used to drain out urine, this is called catheterization. These are used in patients who have medical conditions such as urinary incontinence and retention, multiple sclerosis, spina-bifida, dementia, and temporarily post-surgery of prostate or genitals. They are made up of latex, polyurethane, or silicone. A Foley catheter comprises a balloon t …
- Genital Warts (Condylomata Acuminata)：グローバル臨床試験レビューH1, 2013Genital Warts (Condylomata Acuminata) Global Clinical Trials Review, H1, 2013 Summary GlobalData's clinical trial report, “Genital Warts (Condylomata Acuminata) Global Clinical Trials Review, H1, 2013" provides data on the Genital Warts (Condylomata Acuminata) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Genital Warts (Condylomata …
- 調理済み冷凍食品の世界市場2016-2020About Frozen Ready Meals Frozen meals comprise a large portfolio, including beef meals, chicken meals, frozen pizza, and various types of frozen vegetarian meals, thereby providing consumers with a large variety of options to choose from. Frozen ready meals are a convenient alternative to cooking and are increasingly being preferred by the working population worldwide. Frozen meals are perceived t …
- 心臓再同期療法除細動器（CRT-D） の世界市場2016-2020About the Cardiac Resynchronization Therapy Defibrillator (CRT-D) Market Heart failure, a condition when the heart cannot pump enough blood to meet the body’s need, is one of the leading causes of death. Heart failure and stroke, if occurred together, can lead to major health problems or cause sudden death. Irregularity in ventricular rate can lead to reduction of diastolic dysfunction, a conditio …
- グローバル小売市場におけるイノベーション及びトレンドSummary “Global Retail Innovations” report, published by Conlumino, covers some of the key in-use and new retail innovations utilized by retailers across the world, to effectively engage consumers across a host of platforms, including mobile and social media, virtual and augmented reality, in-store and online displays/visibility. Also aims to understand some of the key trends which influence innov …
